Dr. Anthony Fauci, the U.S. President Joe Biden's chief medical advisor, told The Hill this week that the vaccines will be ready by the fall. The vaccine may become less effective once the Omicron subvariant is replaced by another strain, a real possibility given that dominant strains have been replaced with more competitive forms of the virus roughly every six months.
He said on The Hill'sRising that he was dealing with a moving target. It is possible that the evolution of another variant will be slightly different than the BA.5 but not completely different.
The White House and vaccine makers want to head off a worse outcome by speeding up the development of a universal COVID vaccine.
Pfizer, Moderna, and other pharmaceutical executives were at the White House on Tuesday to discuss a vaccine. The vaccine that is going to be far more durable, that are going to provide far longer- lasting protection, is what the White House is talking about.
Pfizer may have an advantage.
Pfizer announced the start of phase II trials for its new universal vaccine candidate that would protect against both the original COVID strain and Omicron variant.
The director of Regenerative Medical Health wrote on his account that he was besides himself. There is a need for a pan-Coronaviruses vaccine.
Making a new vaccine every time a new variant pops up is not a good idea according to some experts.
According to Eric Topol, the development of variant-specific boosters won't keep up with the pace of emerging new variations. Variant chasing is a bad strategy according to him. It is temporally flawed and not acceptable.
The Omicron-specific boosters seem to be on their way. The FDA asked vaccine makers to make changes to their vaccines. The majority of cases recorded in the US are BA.5. An explosion of cases has been caused by the BA.5 wave. The US is currently reporting 131,000 cases per day, but sewage samples show that the figure could be several times higher.
Pfizer said it would modify its vaccine to fit BA.5.
The CEO of BioNTech, which originally developed the vaccine marketed by Pfizer in the U.S., said that Omicron has newly evolving sublineages that have outcompeted BA. If epidemiological and laboratory data suggest, we will adapt our Omicron-adapted vaccine candidates to emerging sublineages.
Moderna announced on July 11 that its BA.5 booster boosted a person's immunity to a vaccine.
Stephane Bancel, CEO of Moderna, said in a statement that the platform continues to demonstrate better performance than the current booster. Multiple Phase 1/3 studies have shown that the immune response following a bivalent booster is superior.
The variant-specific vaccines could be ready by October.
Biden, who tested positive for COVID last week, acknowledged how evasive the BA.5 variant is, even as vaccines, boosters, and therapeutic are blunting the deadlines and severity of the current wave.
Biden said at the White House's Rose Garden on Wednesday that many people are still going to get carbon dioxide even if precautions are taken. Biden said that if you get a vaccine, you can avoid a serious case.
If you sign up for the email list, you will be kept up to date with our biggest features, exclusive interviews, and investigations.
All Rights Reserved © 2024
